Unknown PHASE3 INTERVENTIONAL 2-arm NCT01258842

Bifidobacterium Lactis HN019 Supplementation for Prevention of Influenza Infection in Healthy Adults

Double-blind, Randomized, Placebo-controlled Trial of the Effects of Prophylactic Bifidobacterium Lactis HN019 Supplementation on the Incidence of Influenza Infection in Healthy Adults

Sponsor: Danisco

Conditions Influenza

Interventions Bifidobacterium lactis HN019 Placebo

Updated 5 times since 2017 Last updated: Dec 10, 2010 Started: Dec 31, 2010 Primary completion: May 31, 2011 Completion: May 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Influenza and is currently ongoing. Danisco leads this study, which shows 5 recorded versions since 2010 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE3
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE3
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE3

First recorded

Dec 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Danisco
Fonterra Research Centre
Sprim Advanced Life Sciences

Data source: Fonterra Research Centre

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Coral Gables, United States
• Rochester, United States